A survey of more than 5,000 Americans conducted with Ipsos found that insured Americans want better health care coverage. These insights come from the third installment of the Patient Experience Survey and show how Americans favor policy solutions that improve their ability to navigate and access their care by seeking to remove barriers imposed by insurers and middlemen such as pharmacy benefit managers (PBMs).
Here are three key findings, along with patients’ direct perspectives, from the latest PES report.
- To insured Americans, better coverage means lower out-of-pocket costs, increased transparency and more predictability.
Fifty-eight percent of insured Americans say they are willing to pay more for their health insurance premiums if it means having more services and prescriptions medicines covered. Moreover, 90% of insured Americans say they want more predictability in health care so that people know how much they will pay for things like prescription drugs every month.
- Patients want to eliminate inefficiencies introduced by insurance companies and PBMs.
Eighty-three percent of insured Americans say health care costs would be lower if insurance companies and PBMs spent less time managing how medicines should be prescribed by doctors.
- Insured Americans support reforms that pass along the savings and make health care coverage more affordable.
Eighty-nine percent of insured Americans support requiring Part D insurance plans and PBMs to directly pass on any rebates or discounts on prescription drugs at the pharmacy counter. One-third (33%) support reducing the burden of deductibles by requiring insurance plans to cover more products and services before a deductible is met; it was the top ranked solution among 12 options listed.
It’s clear that Americans want to address their true concerns around health coverage to deliver improved access to care and lower out-of-pocket costs. To learn more about challenges Americans face as they navigate the health system and solutions that seek to alleviate these challenges, visit PhRMA.org/Middlemen.
PhRMA’s Patient Experience Survey (PES) is a research initiative to explore the challenges Americans face as they navigate the health care system. The poll was conducted among 5,103 American adults (age 18 or older), including 4,720 with insurance, from May 23 – June 1, 2022, using Ipsos’ probability-based KnowledgePanel®, and it is representative of the American adult population. The margin of sampling error is plus or minus 1.5 percentage points at the 95% confidence level, for results based on the entire sample of adults. The latest PES also features qualitative data from hours of in-depth interviews.
Tom Wilbur
Tom Wilbur is Deputy Vice President of Public Affairs at PhRMA where he leads the state public affairs team and Voters for Cures, PhRMA’s grassroots advocacy initiative. Prior to joining PhRMA in 2019, Tom served as a senior aide on Capitol Hill for U.S. Rep. Fred Upton and the House Energy and Commerce Committee. Tom holds an M.A. in strategic communications from Michigan State University and a B.A. in social science and history from Central Michigan University. He enjoys spending time with family and friends, volunteering, reading and golfing.
Survey confirms too many insured Americans face barriers to reliable health care
CMS’ MFN proposals won’t help seniors despite lofty promises
Voters voice concerns on government price controls
Americans believe U.S. pharma leadership needs to be protected
50-state poll says Americans are concerned that hospital markups hurt patients
Health care practitioners sound the alarm on middlemen-imposed barriers to patient care, need for policy change
New PES survey: Out-of-pocket costs lead key health care priorities ahead of the November election
Americans speak out on health insurance barriers and need for policy change, according to the latest Patient Experience Survey
Where voters stand ahead of the election
Key voter insights two months from Election Day
Three things to know about the United Nations’ new HIV/AIDS report
Voters across all 50 states want state policymakers to focus on health insurance and PBM practices
Case study: How seniors could face access disruptions because of the IRA’s price setting provisions
New 50-state poll Americans want to hold health insurers and PBMs accountable for high out-of-pocket costs and other practices
ICYMI: What patients care about this election year
ICYMI: Misaligned policies undermine patient access
Key election year voter insights
ICYMI: Voter priorities this election season
3 Takeaways from POLITICO’s Health Care Summit
Voter insights: Four things to know
New poll: Americans agree that expanding the TRIPS waiver will harm U.S. global manufacturing and innovation leadership
New analysis of patient access restrictions in the United Kingdom
ICYMI: 3 takeaways on the IRA’s unintended consequences from America’s Physician Groups’ 2023 annual fall conference
One year to Election Day: Four voter priorities to watch
New poll shows strong bipartisan support for PBM reform
Navigating the Patient Experience Survey: Protecting Lifelines to Access and Innovation
Three things to know from the latest Patient Experience Survey
4 Things to know about PhRMA’s new 50-state poll
Americans want state policymakers to lower out-of-pocket costs
States can support access to medicine as COVID-19 Public Health Emergency ends
Key Trends: Patient experience data reveal how insurers and middlemen impose barriers in health care
Recognizing National Glaucoma Awareness Month
Minnesota lawmakers are letting PBMs off the hook, and threatening patients’ access to medicines
In their own words: Financial barriers exacerbate access challenges for insured Americans
In their own words: Insured Americans struggle to navigate complex coverage
Mental Illness Awareness Week – A time for reflection
Navigating the patient experience: Burdens and barriers standing between patients and their care
New survey: Voters seriously concerned about fine print in reconciliation bill
This week’s reading list: All the reasons the Senate-passed drug pricing bill is bad policy
Myth vs. Fact: The Senate’s latest price setting proposal
ICYMI: Patients across the country are sharing concerns about government price setting
New analysis finds deeper impact of drug pricing bill on biopharmaceutical researchers
ICYMI: A patient, physician, biotech investor and industry leaders warn about the dangers of government price setting bill
Survey Says: Prescription drug prices are not fueling inflation concerns for Americans
The Patient Perspective: Government price-setting harms patients
Polling continues to show voters reject so-called Medicare “negotiation” once they learn about consequences for patients
3 things voters are concerned about when it comes to their health care coverage
CMS coverage decision restricts access to treatments for Alzheimer’s disease
Patients support state action requiring PBMs and insurers to share savings and cap costs for medicines
New poll shows voters sounding the alarm on health insurance companies and PBMs
Report finds PBMs are increasingly restricting patient access to medicines
Spotlighting a growing mental health challenge
Study finds insurance barriers disproportionately burden patients with chronic illness
5 public opinion polling trends to watch
The patient experience: Uncovering the barriers to care for insured Americans
The patient experience: Insurance barriers continue to impede access to health care, especially among the country’s underserved
New poll of all 50 states and 435 Congressional Districts shows perils of so-called Medicare “negotiation”
Navigating the patient experience in the time of COVID-19
Insurance design barriers can impact patient adherence and can lead to poor health outcomes
ICYMI: PhRMA CEO speaks at STAT Summit about government price setting
Three things to know about so-called Medicare negotiation polling
The patient experience: Insurance design hurdles lead to access issues for too many Americans
The patient experience: Out-of-pocket costs are driving patients affordability and access challenges
New poll shows Americans reject Medicare negotiation once they learn more about the policy
What is Kaiser Family Foundation up to?
New report shows 3 in 10 Americans that have insurance still face a financial barrier to care
Recent polling misrepresents public support for Medicare “negotiation”
Myth vs. fact: Polling and Medicare “negotiation”
Data shows voters strongly support protecting access to their medicines
Data shows COVID-19 vaccines are creating a pathway to a strong U.S. recovery
New polling shows Americans are sounding the alarm on the TRIPS IP waiver
Four solutions Americans support to make health care more affordable
Data shows that Americans are relying on vaccines to get us through the pandemic
Data shows that keeping a strong biopharmaceutical industry is important to Americans
Getting the 340B program back on track in 2021
Top five issues voters want addressed in the administration’s first 100 days
Growing trend: Increased vaccine confidence
The latest misleading “poll” on drug pricing
Election insights: Common ground areas to address Americans’ health care concerns
Election insights: Voter priorities in the states
Insights from the election: Meeting voters where they are on health care
Deep dive: The issues that drove the 2020 vote
Voters want to address the real drivers of health care costs for patients and the system
Three things you should know about recent health care polling
Growth in innovative, value-based contracts holds promise for the health system and for patients
Innovative contracts drive access for patients and value for the system
ICYMI: Patients saved nearly $800,000 out of pocket through innovative contracting arrangements
PhRMA comments on HHS proposed rule on manufacturer cost-sharing assistance and accumulator adjustment programs
Addressing barriers that inhibit value-based contracts
New data show how ICER’s value framework could prevent or delay access to treatments for Medicaid patients across the country
Guest Post: Following my stroke, having access to ground-breaking medical innovation has never been more important
Setting the record straight on international reference pricing
Fact Check: How the Part B International Pricing Index model threatens patient access
New analysis shows 820,000 prescriptions would be in jeopardy if ICER’s value framework is used in Medicaid
PhRMA comments to administration on Medicare Part D proposed rule
Keep the Six Protected Classes, protected
ICYMI: New study reinforces dangers of proposed IPI model
Groups sound the alarm on administration’s new Part B proposal
4 things you need to know about the administration’s latest Part B proposal
PhRMA submission to the 2019 National Trade Estimate Report urges action to protect U.S. biopharmaceutical innovation
What if a couple of small fixes could protect seniors in the donut hole and save them money on out-of-pocket costs?
How much do you know about Medicare Part B?
ICER’s budget impact threshold: Sounding a false alarm on affordability and access
PhRMA submission to HHS on blueprint to lower drug prices and reduce out-of-pocket costs
Event next week: Supporting the next generation of lifesaving medicines
How ICER’s assessment of a new class of migraine treatments fails patients
Guest post: Excellent care for LGBTQ patients requires cultural humility and specific medical knowledge
New analysis shows that more medicines worldwide are available to U.S. patients
New analysis shows that HTA organizations may frequently restrict access to cancer treatments
New analysis shows negative impact of ICER’s value framework on patient access in Medicare Part B
Event tomorrow: Improving patient access to lifesaving medicines
New 340B analysis: Hospitals raking in billions while uncompensated care drops by billions
Event tomorrow: Making the biopharmaceutical supply chain work for patients
New report shows over 500 medicines in development for neurological disorders
PPA celebrates 13 years of helping patients access their medicines
Copay coupons can help ease patients’ out-of-pocket costs
Fact Check Friday: The truth about the cost of 340B to patients
PhRMA launches new consumer-facing Let’s Talk About Cost website
340B Spotlight: New pieces of legislation continue momentum to fix 340B program
Video: What is a results-based contract?
340B Spotlight: ICYMI – 340B hearing, new reports highlight growing need for program reform
How much are hospitals marking up the price of medicines? The answer may surprise you.
VIDEO: PhRMA CEO discusses industry response to opioid crisis on Mornings with Maria
Foreign government price setting by any name harms innovation and access to medicines
Compulsory licensing: A misused and abused international trade law
Government-imposed price controls threaten innovation and access
Medicare Monday: A discussion on affordability and access to medicines
17 years (and more) of medical discoveries
How do multiple sclerosis patients define value?
ICYMI: New era of medicine initiative kicks off in Boston
Biopharmaceutical industry’s success reducing disparities for African Americans
Medicare Monday: What is IPAB, and why is it bad for patients?
In their own words: Insured Americans support policy reforms that address access and affordability concerns
Access
Patients
Polling
In their own words: Insured Americans support policy reforms that address access and affordability concerns
In their own words: Insured Americans support policy reforms that address access and affordability concerns